Suppr超能文献

HLA配型不匹配与心脏、心肺及单肺移植的结果

HLA mismatching and outcome in heart, heart-lung, and single lung transplantation.

作者信息

Keogh A, Kaan A, Doran T, Macdonald P, Bryant D, Spratt P

机构信息

Cardiopulmonary Transplan Unit, St. Vincent's Hospital, Sydney, NSW, Australia.

出版信息

J Heart Lung Transplant. 1995 May-Jun;14(3):444-51.

PMID:7654729
Abstract

BACKGROUND

To determine the influence of HLA mismatching on rejection after cardiothoracic organ transplantation, we analyzed results in 243 recipients.

METHODS

There were 183 heart, 25 heart-lung, and 35 single lung recipients, all receiving triple-drug immunosuppression with anti-thymocyte globulin induction. Zero, one, and two mismatches occurred by chance at each locus in between 0% to 9%, 26% to 35%, and 47% to 70% of recipients, respectively.

RESULTS

In heart recipients, compared with a two mismatch, a zero mismatch was associated with a lower linearized rejection rate in the first 6 months. A zero B locus mismatch was likewise associated with less rejection in month 1, and DR zero mismatch with reduced rejection in the first 3 months. Steroid withdrawal was more successful in those with zero mismatch at any locus. In heart-lung recipients linearized rejection was significantly lower in those with lesser degrees of A and DR locus mismatching, and after single-lung transplantation linearized rejection was significantly lower with lesser degrees of A and B locus mismatching from 3 to 6 months only. Actuarial survival did not differ for any organ with any degree of mismatch at any locus.

CONCLUSIONS

HLA mismatching affects rejection, but the effect is limited to the early postoperative period for heart and heart-lung recipients. Lower grades of mismatch increase the likelihood of successful steroid withdrawal for heart recipients. The chance occurrence of no mismatch at any locus is rare, making prospective matching infeasible. HLA mismatching identifies patients at higher risk of rejection. The best use of this information may be to guide early immunosuppression, limiting prospective matching to retransplants or with presensitized recipients.

摘要

背景

为了确定人类白细胞抗原(HLA)错配在心胸器官移植后对排斥反应的影响,我们分析了243例受者的结果。

方法

有183例心脏、25例心肺和35例单肺受者,均接受抗胸腺细胞球蛋白诱导的三联药物免疫抑制治疗。每个位点出现零个、一个和两个错配的受者比例分别为0%至9%、26%至35%和47%至70%。

结果

在心脏受者中,与两个错配相比,零个错配与前6个月较低的线性化排斥率相关。B位点零个错配同样与第1个月较少的排斥反应相关,DR位点零个错配与前3个月减少的排斥反应相关。在任何位点零个错配的患者中,停用类固醇更成功。在心肺受者中,A和DR位点错配程度较低的患者线性化排斥反应显著较低,而在单肺移植后,仅在3至6个月时,A和B位点错配程度较低的患者线性化排斥反应显著较低。任何器官在任何位点任何程度的错配,其精算生存率均无差异。

结论

HLA错配会影响排斥反应,但这种影响仅限于心脏和心肺受者术后早期。较低程度的错配增加了心脏受者成功停用类固醇的可能性。任何位点无错配的偶然情况很少见,使得前瞻性配型不可行。HLA错配可识别排斥反应风险较高的患者。该信息的最佳用途可能是指导早期免疫抑制,将前瞻性配型限制在再次移植或致敏受者中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验